Ceftobiprole is a new parenterally administered fifth generation cephalosporin which has been shown to have antimicrobial activity against a broad range of bacteria, and specifically against methicillin-resistant Staphylococcus aureus (MRSA) in complicated skin and skin structure infections (cSSSIs), with a cure rate non-inferior to vancomycin and ceftazidime. It has increased stability against β-lactamases and an increased affinity for PBP2 in MRSA strains. Ceftobiprole has shown a low tendency to select for resistance, and because it is excreted mainly in the urine, a low potential for adverse drug interactions. It has been shown to cause few mild to moderate adverse effects in patients. The broad-spectrum of activity makes it an excellent choice for initial monotherapy in cSSSIs. There is also promise for use in all types of pneumonia, and synergistic possibilities with aminoglycoside and fluoroquinolone drugs. It is awaiting final approval by the FDA.
PDF (529.03 KB PDF FORMAT)
RIS citation (ENDNOTE, REFERENCE MANAGER, PROCITE, REFWORKS)
BibTex citation (BIBDESK, LATEX)
I was pleased to serve as a peer reviewer for Clinical Medicine Insights: Therapeutics. Its scope will hopefully blur some of the lines that still exist between clinical and basic science. The diligence of the editorial staff ensures the review process is fair, fast and very well-organized. I highly recommend potential authors and reviewers to submit to and review for this journal.
All authors are surveyed after their articles are published. Authors are asked to rate their experience in a variety of areas, and their responses help us to monitor our performance. Presented here are their responses in some key areas. No 'poor' or 'very poor' responses were received; these are represented in the 'other' category.See Our Results
Copyright © 2013 Libertas Academica Ltd (except open access articles and accompanying metadata and supplementary files.)